QURE News and Press, uniQure N.V. From 10/15/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Today, we take an in-depth look at Dutch biopharma concern UniQure for the first time in 2021. The company is slowly advancing its pipeline, is cash rich and has picked up increasing positive analyst support of late. A full investment analysis and recommendation are provided in th...

According to a recent report from MarketsAndMarkets.com, the global Parkinson’s disease treatment market is expected to reach $5.69 billion by 2022, growing from $4.24 billion in 2017, expanding at a CAGR of 6.1%.  The report notes that this market is being driven by rising geriat...

Match Group, Ceridian HCM and Brown & Brown Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 Match Group, Ceridian HCM and Brown & Brown Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire...

Match Group (NASDAQ:MTCH), Ceridian HCM Holding (NYSE:CDAY) and Brown & Brown (NYSE:BRO) are moving into the S&P 500 as part of the index's quarterly rebalancing. They're higher postmarket: MTCH +9%, CDAY +1.3%, BRO +1.5%. They're replacing three companies moving out as their market c...

Gainers: QURE +9.6%. MTCH +7.6%. HCSG +5.6%. WW +3.1%. ANPC +2.0%. Losers: CDZI -4.4%. NMIH -3.8%. KPLT -3.3%. VERA -3.1%. XM -2.4%. For further details see: QURE, MTCH, CDZI and NMIH among after hours movers

~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~ ~ Full Study Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene the...

uniQure (QURE): Q2 GAAP EPS of $8.51 beats by $6.91.Revenue of $463.9M (+30023.4% Y/Y) beats by $320.92M.As of June 30, 2021, the Company’s cash position was $677.3M. The Company expects cash and cash equivalents will be sufficient to fund operations into the first half of 2024, exclud...

~ Expanded gene therapy pipeline with four new research programs and announced acquisition of Corlieve Therapeutics ~ ~ Presented positive 52-week data from HOPE-B pivotal study demonstrating sustained increases in Factor IX (FIX) levels with mean FIX activity of 4...

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations, of which three are ora...